Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, Edward Drea, PharmD

Blood (2019) 134 (Supplement_1): 2203.

https://doi.org/10.1182/blood-2019-124319

Published: 2019

Journal Articles

Heme Overload Triggers Xanthine Oxidase Release and Mediates the Inflammatory Response

Heidi M Schmidt, BSE, Eric Kelley, PhD, Adam Straub, PhD

Blood (2019) 134 (Supplement_1): 3529.

https://doi.org/10.1182/blood-2019-130274

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

Ghassan Al-Shbool, MD, Sameer Desale, MS, Judith Veis, MD, Vera Malkovska, MD, Sanjal Desai, MD

Blood (2019) 134 (Supplement_1): 2912.

https://doi.org/10.1182/blood-2019-129558

Published: 2019

Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM

Blood (2019) 134 (Supplement_1): 2914.

https://doi.org/10.1182/blood-2019-128755

Published: 2019

Journal Articles

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Kylee L Martens, MD, Parisa R Khalighi, BS, Shan Li, PharmD, Andrew A White, MD, Emily Silgard, MS, Deborah Frieze, PharmD, Elihu H. Estey, MD, David A. Garcia, MD, Sangeeta R Hingorani, MD MPH, Ang Li, MD

Blood (2019) 134 (Supplement_1): 4674.

https://doi.org/10.1182/blood-2019-124058

Published: 2019

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

John McKay, DO, Matthew Gayhart, MD, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Edward B. Perkins, MD PhD

Blood (2019) 134 (Supplement_1): 5140.

https://doi.org/10.1182/blood-2019-129429

Published: 2019

Journal Articles

Is There Any Impact of Uric Acid Levels during the Peri-Transplant Period on Acute Graft Vs. Host Disease Incidence and Allotransplant Outcome?

Panayotis Kaloyannidis, Hussin Alsubaie, MD, Rawan Omari, MD, Solaf Kanfar, MD, Zahra Abdrabalamir Alshammasi, MD, Mohammed Darweesh, MD, Enas Mutahar, MD, Kenana Ajlan, Technician, Abdulhamid Liacini, Norah Muhlem, Technician, Ahmed Bahrani, MD, Afra Dayel, MD, John Apostolidis, MD, Hani Al Hashmi, MD, Khalid Ahmed Al-Anazi, MD

Blood (2019) 134 (Supplement_1): 5681.

https://doi.org/10.1182/blood-2019-128651

Published: 2019

Journal Articles

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Haiyan Yang, Tao Lei, Cong Li, Haifeng Yu, Zhongjian Chen

Blood (2019) 134 (Supplement_1): 5234.

https://doi.org/10.1182/blood-2019-129897

Published: 2019

Journal Articles

Tumor Lysis Syndrome Management in Community Oncology Settings

Scott Howard, MD

Blood (2019) 134 (Supplement_1): 5875.

https://doi.org/10.1182/blood-2019-132266

Published: 2019

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Mateo Mejia Saldarriaga, MD, Amir Steinberg, MD, Adam F. Binder, MD

Blood (2018) 132 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2018-99-112652

Published: 2018

Journal Articles

Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data

Regina M Myers, MD, Kelly D Getz, PhD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Rebecca Citrin, MD, Caitlin W Elgarten, MD, Benjamin L Laskin, MD, Joseph P. Horowitz, Brian T. Fisher, DO, Richard Aplenc, MD PhD

Blood (2018) 132 (Supplement 1): 830.

https://doi.org/10.1182/blood-2018-99-114883

Published: 2018

Journal Articles

A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease

Jennell White, PhD, Xiufeng Gao, MD, Ke Liu, PhD, Michael U. Callaghan, MD, Patrick C. Hines, MD PhD

Blood (2018) 132 (Supplement 1): 1097.

https://doi.org/10.1182/blood-2018-99-120311

Published: 2018

Journal Articles

Tumor-Lysis Syndrome in Relapsed or Refractory Multiple Myeloma Patients Treated with Proteasome Inhibitors

Kazuhito Suzuki, MD, Kaichi Nishiwaki, MD, Tadahiro Gunji, MD, Mitsuji Katori, MD, Rika Hosoba, MD, Kei Hirano, MD, Hidekazu Masuoka, Shingo Yano, MD PhD

Blood (2018) 132 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2018-99-114822

Published: 2018

Journal Articles

Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia

Lena E. Winestone, MD MSHP, Kelly D Getz, PhD, Yimei Li, PhD, Evanette Burrows, MPH, Michael Scheurer, MPH, PhD, M. Monica Gramatges, MD PhD, Jennifer J. Wilkes, MD, Tamara P. Miller, MDMSc, Alix E. Seif, MD, Robert W. Grundmeier, MD, Karen R. Rabin, MD PhD, Brian T. Fisher, DO, Richard Aplenc, MD PhD

Blood (2018) 132 (Supplement 1): 369.

https://doi.org/10.1182/blood-2018-99-120076

Published: 2018

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

NARROW

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Heme Overload Triggers Xanthine Oxidase Release and Mediates the Inflammatory Response

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

Is There Any Impact of Uric Acid Levels during the Peri-Transplant Period on Acute Graft Vs. Host Disease Incidence and Allotransplant Outcome?

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Tumor Lysis Syndrome Management in Community Oncology Settings

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data

A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease

Tumor-Lysis Syndrome in Relapsed or Refractory Multiple Myeloma Patients Treated with Proteasome Inhibitors

Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only